• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Contract Manufacturing: Trials & Tribulations of Today’s Supply Chains

    Analytical Testing in Nutraceuticals: Methods and Mindsets to Uphold Quality

    Nutrition and Flavor: Formulating for Modern Product Preferences

    What Do Consumers Know About the Gut Microbiome?

    How Will the European Green Deal Impact Dietary Supplements?
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process

    ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market

    Tazo Transitions to Regenerative Organic Agriculture

    Protein Ingredient Formulated for Chronic Kidney Disease Patients

    IADSA Calls for Addressing Discrepancies in Vitamin C Recommendations
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Fact or Myth: Antioxidants Negatively Impact Iron Absorption

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process

    ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market

    Tazo Transitions to Regenerative Organic Agriculture

    Protein Ingredient Formulated for Chronic Kidney Disease Patients
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Fact or Myth: Antioxidants Negatively Impact Iron Absorption

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process

    ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market

    Tazo Transitions to Regenerative Organic Agriculture

    Protein Ingredient Formulated for Chronic Kidney Disease Patients
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process

    Caffeine-Free Energy Supplement Linked to Alertness, Fatigue Benefits

    Monk Fruit Sweetener May Have Prebiotic Activity, Study Finds

    People with Low-Fiber Diets Benefit the Most from Fiber Supplements, Study Finds

    Gut Microbiome May Be Part of Link Between Red Meat and Heart Disease Risk
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    Sabinsa Corporation

    Xsto Solutions

    Ecuadorian Rainforest

    Atlantia Clinical Trials

    KLK OLEO
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    Sabinsa Corporation

    Xsto Solutions

    Ecuadorian Rainforest

    Atlantia Clinical Trials

    KLK OLEO
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Online Exclusives

    AMR101 Takes on Lovaza

    Amarin enters final phase of testing for its promising fish oil medication for high cholesterol.

    Related CONTENT
    • Qualitas Health Enters Production Partnership
    • AHPA Encourages EPA to Reform Pesticide Regulations
    • Nature Made Introduces Four New Supplements
    • Coromega to Showcase Coromega Max and Women’s Health Omega-3 Supplements
    • Coalition Forms to Fight Food Waste
    Joanna Cosgrove11.08.10
    For patients with hypertriglyceridemia—a dangerous condition characterized by a triglyceride level over 500 mg/dL—a popular and effective therapy of late has been the fish oil-based pharmaceutical Lovaza from GlaxoSmithKline (GSK)*, coupled with statin therapy. But a new, more specialized fish oil medication from Amarin Corp., of Dublin, Ireland, recently entered Phase III clinical trials and is poised to siphon valuable market share from Lovaza.
     
    Dubbed AMR101, the product is an ultra pure (>96%) ethyl ester of eicosapentaenoic acid (ethyl-EPA), a long chain highly unsaturated fatty acid in the omega 3 class. Amarin believes the product to have a beneficial impact on such biological factors as anti-inflammatory mechanisms, cell membrane composition and plasticity and regulation of glucose metabolism, though its impact on triglyceride levels is an area buoyed by the most clinical promise.
     
    In an interview with Nutraceuticals World, Declan Doogan, MD, Amarin’s chief medical officer, talked about three key points of difference that will likely pit AMR101 squarely against GSK’s Lovaza.
     
    For starters, AMR101 is pure EPA and doesn’t contain any DHA. Amarin is confident that the absence of DHA confers distinct advantages in the quest to lower high triglycerides. “DHA is associated with elevations in LDL cholesterol. Because AMR101 doesn’t have DHA, we believe we will be without the LDL signal to the same extent as Lovaza,” he explained. “What’s important to understand is that Lovaza, when given with a statin is still associated with an elevation of LDL so therefore in many cases you would still have to adjust the dose of the statin. AMR101 is cleaner in that when you combine AMR101 and a statin, you should not get this LDL change. We believe it will be an easier drug for doctors to prescribe than Lovaza.”
     
    In addition to cutting out the DHA effect, AMR101 has also demonstrated its efficacy in half the dose of Lovaza. “The dose of Lovaza is four grams (or four capsules) per day for patients with very high triglycerides of 500 or above,” Dr. Doogan said. “With AMR101 the dose is likely to be two grams or two capsules for the same population, which is still to be proven in our clinical trials but that’s the plan.”
     
    The third differentiation relates to the medication’s lack of a fishy aftertaste, which Dr. Doogan attributed to the nonexistence of DHA in the formulation.
     
    “The question may be asked ‘Yes, but what do you lose by taking DHA out of AMR101 or fish oil?’ I don’t believe you lose anything,” he said. “If you’re using this drug as a treatment for vascular disease and cardiovascular complications, we have data to show in 19,000 patients if you add AMR101 or 96% EPA to a statin, compared with a statin alone you will get an additional 19% reduction in coronary events. You turbo-charge the statin when you give AMR101. That’s saying that pure EPA alone will do the business.”
     
    He also added that although DHA is excluded from AMR101 it doesn’t mean DHA doesn’t have a place in the nutraceutical landscape. “DHA is an integral component of nutritional supplements and food preparations for children, such as baby formulas,” he said. “It’s very important for the maturing brain and retinas. But that’s a very different proposition than managing adult cardiovascular events.”
     
    He additionally acknowledged the benefits of nutraceutical grade omega 3. “I understand the value of nutraceutical supplementation of omeg -3 as well as the nutraceutical market for omega 3. As a physician, I would recommend omega 3 as a wellness product,” he said. “But when somebody comes to the doctor with substantially elevated triglycerides (500+) I would strongly believe that the doctor would want to prescribe a well-tried and tested formulation and dose of omega 3 and that’s the reason for the likes of Lovaza and AMR101.”  
     
    Mounting Research
     
    Amarin’s AMR101 EPA formulation is not entirely unique, as pure EPA has been available in Japan (marketed by Mochida as Epadel) for a decade and has been extensively researched. In fact, according to Amarin, a study called JELIS demonstrated that EPA plus statins reduced coronary events in at-risk patients by about 19% compared to statins alone. Based on this evidence, there is quiet confidence that the two current Phase 3 AMR101 trials will be successful.
     
    The first trial, called Marine, is set to examine about 250 of the same patients targeted by Lovaza—those, for example, who have triglyceride levels above 500 mg/dL.
     
    The second trial, called Anchor, will look at patients with triglyceride levels above 250mg/dL and below 500 mg/dL, who also are receiving statin therapy for high LDL cholesterol. This group has what is referred to as mixed dyslipidemia. According to Amarin, this trial aims to extend the prescription label for AMR101 to a population that Lovaza is not approved to treat.
     
    There are approximately 10 times more patients in this group than the population Marine/Lovaza targets. This trial is expected to complete recruitment of approximately 650 patients in early 201.
     
    “We have masses of data on the drug to show that it’s safe and to show our confidence in the drug’s effect on triglycerides and also cardiovascular disease,” Dr. Doogan concluded.
     
    Results for the Marine trial are expected in early 2011, with Anchor trial results to follow. Dr. Doogan said he expected an application to the FDA to be filed shortly thereafter. 
     
     
    *When contacted, GSK declined the opportunity to make a statement, citing company policy not to comment on products that are not yet at market.
    Related Searches
    • Nutraceuticals
    • Nutritional
    • Regulation
    • Nutraceutical
    Related Knowledge Center
    • Cardiovascular Health
    • Research
    Suggested For You
    Qualitas Health Enters Production Partnership Qualitas Health Enters Production Partnership
    AHPA Encourages EPA to Reform Pesticide Regulations AHPA Encourages EPA to Reform Pesticide Regulations
    Nature Made Introduces Four New Supplements Nature Made Introduces Four New Supplements
    Coromega to Showcase Coromega Max and Women’s Health Omega-3 Supplements Coromega to Showcase Coromega Max and Women’s Health Omega-3 Supplements
    Coalition Forms to Fight Food Waste Coalition Forms to Fight Food Waste
    NARB Recommends Novartis/GSK Discontinue Benefiber Claim: ‘Helps Maintain Regularity’ NARB Recommends Novartis/GSK Discontinue Benefiber Claim: ‘Helps Maintain Regularity’
    Weight Loss & Sexual Enhancement Products Recalled Weight Loss & Sexual Enhancement Products Recalled
    GlaxoSmithKline Recalls Alli GlaxoSmithKline Recalls Alli
    Amarin Receives $100 Million in Financing Amarin Receives $100 Million in Financing
    Amarin Announces FDA Approval of Vascepa for the Reduction of Triglyceride Levels Amarin Announces FDA Approval of Vascepa for the Reduction of Triglyceride Levels
    Growth Opportunities in Sports Nutrition Growth Opportunities in Sports Nutrition
    FDA Accepts NDA Filing for Amarin FDA Accepts NDA Filing for Amarin
    FDA Accepts NDA Filing for Amarin FDA Accepts NDA Filing for Amarin
    Epanova Phase III Trial Begins Epanova Phase III Trial Begins
    GSK Acquires U.K.’s Top Sports Nutrition Company GSK Acquires U.K.’s Top Sports Nutrition Company

    Related Breaking News

    • Breaking News | Marine Nutraceuticals | Omega-3s | Supplier News

      Qualitas Health Enters Production Partnership

      Company signs a long-term agreement to triple algae production.
      05.25.17

    • Breaking News | Herbs & Botanicals | Regulations | Regulatory News

      AHPA Encourages EPA to Reform Pesticide Regulations

      AHPA recommended addition of nearly 200 commercially available herbal crops to Crop Group 19, ‘Herbs and Spices.’
      05.22.17

    • Cardiovascular Health | Digestive Health | Immune Function | Men's Health | Products

      Nature Made Introduces Four New Supplements

      Pharmavite brand targets heart health, immune health, digestive health, and men’s health categories.
      05.03.17


    • Coromega to Showcase Coromega Max and Women’s Health Omega-3 Supplements

      Company offering two new fish oil squeezes with omega-3s and vitamin D.
      03.09.17

    • Breaking News | Consumer Trends | Healthcare Trends | Industry & Market News

      Coalition Forms to Fight Food Waste

      Twelve organizations set to launch FurtherWithFood.org, an online hub for information and solutions to cut food waste.
      12.21.16

    Loading, Please Wait..
    Trending
    • First Day Life Shuts Down Children's Behavioral, Cognitive Health Claims Following Challenge
    • Study Examines Vitamin K2 Content In Cheese
    • Chenland Nutritionals Self-Affirms GRAS For Cumin UP60 Ingredient
    • Pycnogenol Evidenced To Have Skin Benefits In Dermatology Study
    • ADM And Benson Hill Partner To Scale High Protein Soy For U.S. Market
    Breaking News
    • Charlotte’s Web Sports Product Line to Undergo NSF Certification Process
    • ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market
    • Tazo Transitions to Regenerative Organic Agriculture
    • Protein Ingredient Formulated for Chronic Kidney Disease Patients
    • IADSA Calls for Addressing Discrepancies in Vitamin C Recommendations
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • A Growing Herbal Products Market Still Faces Formidable Threats, Challenges
    • Analytical Testing in Nutraceuticals: Methods and Mindsets to Uphold Quality
    • Nutrition and Flavor: Formulating for Modern Product Preferences
    • Contract Manufacturing: Trials & Tribulations of Today’s Supply Chains
    • How Will the European Green Deal Impact Dietary Supplements?
    • What Do Consumers Know About the Gut Microbiome?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Charlotte’s Web Sports Product Line to Undergo NSF Certification Process
    ADM and Benson Hill Partner to Scale High Protein Soy for U.S. Market
    Tazo Transitions to Regenerative Organic Agriculture
    Coatings World

    Latest Breaking News From Coatings World

    SONGWON Industrial Group Reports Strong Q2 Financial Results
    PPG Completes COLORFUL COMMUNITIES Project for Boys & Girls Clubs of Greater Houston
    Paul N. Gardner Now Offers Bacharach Sling Psychrometer
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    'Graft-on-a-Chip' Built to Improve Vascular Graft Success
    Abbott Invests €440 in New Irish Facility
    FDA Approves Guardant Health's NGS-Based Companion Diagnostic
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AskBio Appoints Clinical Ops Executives
    SpectrumX Partners With UK Contract Manufacturer
    GL Chemtec Partners with Edgewater Capital to Accelerate Growth
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Arkay Chairman Emeritus Howard Kaneff Has Died
    Nutricosmetics Market to Hit $13.7 Billion by 2030
    Estée Lauder Pledges 100% Electric Fleet of Vehicles by 2030
    Happi

    Latest Breaking News From Happi

    J&J To Stop Global Sales of Talc-Based Products by 2023
    Net Sales Increase 2% for Naples Soap Company in Second Quarter
    Net Revenue Down 12% for Grove Collaborative in Second Quarter
    Ink World

    Latest Breaking News From Ink World

    Heidelberg Enjoys Successful Start to 2022-23 Fiscal Year
    Mimaki Announces New LATAM Website
    Paul N. Gardner Offers Bacharach Sling Psychrometer
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Esko, Constantia Flexibles announce acquisitions and more
    Hybrid Software joins The Flexo Xperience Center
    Flexo Wash LLC and Mike Potter celebrate 20 years
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Focke & Co. to Host Destination: Your Hygiene Hub on August 31
    Exports Dominate Chinese Trade of Tissues, Hygiene Products and Wipes
    Freudenberg to Present Friction Inserts for Wind Energy
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Dental 3D Printing Market is Expanding 20% Annually
    Study Results Released for Abbott's Concussion Blood Test
    Bone Growth Stimulators Market to Top $3B by 2030
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    eMagin Corporation Announces 2Q 2022 Results
    Zebra Technologies’ Emission Reduction Targets Validated by SBTi
    Identiv Delivers Impressive 41% Year-over-Year Growth in RFID Business

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login